Source: Eur Respir Mon; 2003: 27: 84–109
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Delcroix, P. Dorfmüller, M.R. MacLean, J.A. Barbera, M.M. Hoeper, H. Ghofrani, S. Adnot, S. Eddahibi, S. Janssens, A.J. Peacock, J. Pepke-Zaba, D. Vizza, and the other participants of the working group “Pulmonary arterial hypertension”. Pulmonary hypertension: future therapies. Eur Respir Mon; 2003: 27: 84–109

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension in COPD Source: Eur Respir J 2008; 32: 1371-1385 Year: 2008 Pulmonary hypertension in patients with COPD Source: Eur Respir Mon 2012; 57: 138-147 Year: 2012 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Pulmonary hypertension in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 892-905 Year: 2003 Systemic vascular function in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome Source: Eur Respir J 2010; 35: 105-111 Year: 2010 Conclusion: treatment of pulmonary hypertension in COPD patients Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange Year: 2005 Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1 Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Impact of exacerbations on pulmonary arterial enlargement in patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Evidence of renal and pulmonary endothelial dysfunction in chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Novel treatment for pulmonary vascular disease: lessons from pathophysiology Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases Year: 2006 Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 427s Year: 2003 Interleukin-18 production and pulmonary function in COPD Source: Eur Respir J 2008; 31: 287-297 Year: 2008 The burden of pulmonary hypertension Source: Annual Congress 2006 - The burden of pulmonary hypertension Year: 2006